Virios says mid-stage pain trial for lead asset did not reach main goal

Sep. 19, 2022 7:54 AM ETVirios Therapeutics, Inc. (VIRI)By: Dulan Lokuwithana, SA News Editor3 Comments

Definition of the word Fibromyalgia in a dictionary

Zerbor

Clinical-stage biotech Virios Therapeutics, Inc. (NASDAQ:VIRI) announced Monday that the company’s lead candidate, IMC-1, did not achieve statistical significance for the main goal in its Phase 2b trial involving patients with fibromyalgia.

The FORTRESS study, designed to evaluate oral

Recommended For You

Comments (3)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.